ETRACS 2x Leveraged US Growth Factor TR ETN
IWFL
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Leveraged
- Address
- 1285 Avenue of the Americas New York NY United States of America 10019
- IPO Date
- Feb 8, 2021
- CIK
- 0001114446
- Website
- etracs.ubs.com
- Similar Companies
- Business
- ETRACS 2xLeveraged US Growth Factor TR ETN (IWFL) is an exchange-traded note issued by UBS AG that provides two times (2x) leveraged exposure to the total return performance of the Solactive US Growth Factor Total Return Index, which tracks U.S. large-cap growth stocks selected based on growth factor metrics such as earnings growth, sales growth, and momentum; it does not pay dividends and is designed for sophisticated investors seeking amplified daily returns linked to the index before fees and expenses. The ETN offers leveraged investment in the U.S. growth equity segment, targeting institutional and retail investors focused on factor-based strategies, with operations conducted through major U.S. exchanges like the NYSE Arca and global access via UBS's international distribution network; headquartered in Zurich, Switzerland, with primary U.S. listing operations managed from Stamford, Connecticut, the product stems from UBS's long-standing exchange-traded products division established in the early 2000s. In recent developments, UBS announced enhancements to its ETRACS ETN suite in late 2024, including expanded leveraged and inverse offerings amid rising demand for factor-based ETFs amid market volatility; the issuer completed a $500 million funding facility renewal for its ETN program in Q3 2025 to support ongoing issuances, while no major acquisitions or name changes were reported, though UBS integrated new ESG screening options into select growth factor products following regulatory shifts in Europe.